自身免疫性皮肤病患者叙事护理干预方案的应用研究

注册号:

Registration number:

ChiCTR2600121847 

最近更新日期:

Date of Last Refreshed on:

2026-04-03 17:40:02 

注册时间:

Date of Registration:

2026-04-03 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

自身免疫性皮肤病患者叙事护理干预方案的应用研究

Public title:

Application of narrative nursing intervention program for patients with autoimmune skin diseases

注册题目简写:

English Acronym:

研究课题的正式科学名称:

自身免疫性皮肤病患者叙事护理干预方案的应用研究

Scientific title:

Application of narrative nursing intervention program for patients with autoimmune skin diseases

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

董晓兰 

研究负责人:

董晓兰 

Applicant:

Dongxiaolan 

Study leader:

Dongxiaolan 

申请注册联系人电话:

Applicant telephone:

+86 10 6915 6397

研究负责人电话:

Study leader's
telephone:

+86 10 6915 6395

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

dongxiaolan@pumch.cn

研究负责人电子邮件:

Study leader's E-mail:

22286444@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市东城区帅府园一号

研究负责人通讯地址:

王府井帅府园1号(100730)

Applicant address:

No.1 Shuaifuyuan, Dongcheng District, Beijing

Study leader's address:

No.1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京协和医院

Applicant's institution:

Peking Union Medical College Hospital

研究负责人所在单位:

中国医学科学院北京协和医院

Affiliation of the Leader:

Peking Union Medical College Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

I-26PJ0455

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国医学科学院北京协和医院伦理审查委员会

Name of the ethic committee:

PUMCH Institutional Review Board

伦理委员会批准日期:

Date of approved by ethic committee:

2026-02-25 00:00:00

伦理委员会联系人:

李佳月

Contact Name of the ethic committee:

Jiayue Li

伦理委员会联系地址:

王府井帅府园1号(100730)

Contact Address of the ethic committee:

No.1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 69156874

伦理委员会联系人邮箱:

Contact email of the ethic committee:

dott1994@163.com

研究实施负责(组长)单位:

中国医学科学院北京协和医院

Primary sponsor:

Peking Union Medical College Hospital

研究实施负责(组长)单位地址:

王府井帅府园1号(100730)

Primary sponsor's address:

No.1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国医学科学院北京协和医院

具体地址:

王府井帅府园1号(100730)

Institution
hospital:

Peking Union Medical College Hospital

Address:

No.1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing

经费或物资来源:

自身免疫性皮肤病患者叙事护理干预方案的构建与应用研究

Source(s) of funding:

college-level

研究疾病:

经临床与病理确诊为自身免疫性皮肤病(红斑狼疮、硬皮病、皮肌炎、天疱疮、大疱性类天疱疮、疱疹样皮炎、大疱性表皮松解、各种类型银屑病、变应性血管炎、白色萎缩、过敏性紫癜、荨麻疹性血管炎、白癜风、斑秃及全秃等)。  

Target disease:

The clinical and pathological diagnosis of autoimmune skin diseases ( lupus erythematosus, scleroderma, dermatomyositis, pemphigus, bullous pemphigoid, herpetic dermatitis, bullous epidermolysis bullosa, various types of psoriasis, allergic vasculitis, white atrophy, allergic purpura, urticaria vasculitis, vitiligo, alopecia areata and alopecia totalis, etc. )

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

本研究旨在基于ASDs患者的特征分型构建针对性的结构化叙事护理干预方案并检验其有效性,为优化现有护理模式、缓解患者心理困扰、改善生活质量和提高治疗依从性提供理论依据和实践指导。  

Objectives of Study:

The purpose of this study is to construct a targeted structured narrative nursing intervention program based on the characteristics of ASDs patients and test its effectiveness, so as to provide theoretical basis and practical guidance for optimizing the existing nursing model, alleviating patients ' psychological distress, improving the quality of life and improving treatment compliance.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.患有严重精神疾病无法配合者;
2.病情危重如存在严重感染、生命体征不平稳,不宜参与研究者;
3.正在参与其他心理干预相关临床研究者;

Exclusion criteria:

1.Patients with severe mental illness unable to cooperate;
2.Patients with severe infection and unstable vital signs who are not suitable to participate in the study.
3.Patients who are participating in other clinical studies related to psychological interventions;

研究实施时间:

Study execute time:

From 2025-12-01 00:00:00 To 2027-12-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-04-05 00:00:00 To 2027-04-01 00:00:00

干预措施:

Interventions:

组别:

干预组

样本量:

34

Group:

interventional group

Sample size:

干预措施:

分型叙事护理预设干预方案

干预措施代码:

Intervention:

Typed narrative nursing preset intervention program

Intervention code:

组别:

对照组

样本量:

34

Group:

control group

Sample size:

干预措施:

皮肤科常规护理与健康指导。

干预措施代码:

Intervention:

Dermatology routine nursing and health guidance.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京市 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国医学科学院北京协和医院 

单位级别:

三级甲等 

Institution
hospital:

Peking Union Medical College Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

阿森斯失眠量表

指标类型:

次要指标

Outcome:

Athens Insomnia Scale

Type:

Secondary indicator

测量时间点:

入院后、出院前

测量方法:

问卷填写

Measure time point of outcome:

After admission, before discharge

Measure method:

Fill out the questionnaire

指标中文名:

皮肤病生活质量指数

指标类型:

次要指标

Outcome:

Dermatology Life Quality Index

Type:

Secondary indicator

测量时间点:

入院后、出院前

测量方法:

问卷填写

Measure time point of outcome:

After admission, before discharge

Measure method:

Fill out the questionnaire

指标中文名:

一般资料调查表

指标类型:

次要指标

Outcome:

General Information Questionnaire

Type:

Secondary indicator

测量时间点:

入院后

测量方法:

问卷填写

Measure time point of outcome:

after admission

Measure method:

Fill out the questionnaire

指标中文名:

医院焦虑抑郁量表

指标类型:

主要指标

Outcome:

Hospital Anxiety and Depression Scale

Type:

Primary indicator

测量时间点:

入院后、出院前

测量方法:

问卷填写

Measure time point of outcome:

After admission, before discharge

Measure method:

Fill out the questionnaire

指标中文名:

简易疾病感知问卷

指标类型:

次要指标

Outcome:

Brief Illness Perception Questionnaire

Type:

Secondary indicator

测量时间点:

入院后、出院前

测量方法:

问卷填写

Measure time point of outcome:

After admission, before discharge

Measure method:

Fill out the questionnaire

指标中文名:

Morisky用药依从性量表

指标类型:

次要指标

Outcome:

Morisky Medication Adherence Scale-8

Type:

Secondary indicator

测量时间点:

入院后、出院前

测量方法:

问卷填写

Measure time point of outcome:

After admission, before discharge

Measure method:

Fill out the questionnaire

指标中文名:

医学应对方式问卷

指标类型:

次要指标

Outcome:

Medical Coping Modes Questionnaire

Type:

Secondary indicator

测量时间点:

入院后、出院前

测量方法:

问卷填写

Measure time point of outcome:

After admission, before discharge

Measure method:

Fill out the questionnaire

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

纸质问卷表单采集,电子化数据统计管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Paper questionnaire form to collect information,Electronic data statistics management

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-04-03 17:39:54